glp-1 weight loss drug news today 2025 Chart: 1 in 8 Americans Now Use Drugs for ISPOR 2025: Exploring reasons for
Description
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
Computational frameworks transform antagonism to synergy in optimizing combination therapies
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial
3ag, j, k
Bibcode:1993BBRC..196..141G
